BioSpace News Archive

Feb. 19, 2019 06:00 UTC FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma -- Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns -- -- Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease -- SOUTH SAN FRANCISCO, Calif.-

SynTech Nutrition wants to spread the word about heart health during American Heart Month.

Bornfitness.com developed five rules to help you determine if a protein bar passes its test for quality

Probiotics and Prebiotics are not just for your gut; they are the key to healthy, beautiful skin.

Activz Global, LLC is proud to announce the appointment of Vice Admiral Mathias W. Winter to the company’s Board of Advisers.

Former Florida Blue VP Luisa Charbonneau joins Peerfit as Senior Adviser as Digital Health Company Moves into New Market

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, filed its quarterly report for its second quarter of financial year 2019 in a timely manner with the Securities and Exchange Commission.

CASI Pharmaceuticals, Inc. announced that the National Medical Products Administration has approved the Company’s Clinical Trial Application to allow for a confirmatory clinical trial to evaluate the efficacy and safety of ibritumomab tiuxetan injection.

Eleventh Annual Program Awards Seven Grants to Health Care Facilities Across the Nation to Help Advance Patient Care

Acceleron Pharma Inc. announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results.